Conclusions: Hospitalization and long-term costs of carotid artery stenting (CAS) and carotid endarterectomy (CEA) appear similar. Economic considerations should not influence the choice of stenting or surgery in patients with carotid artery stenosis being considered for revascularization.
Summary: CAS is currently associated with an increased risk of 30-day stroke compared with CEA, whereas both interventions seem equally durable beyond the periprocedural period. Although the clinical outcomes continue to be scrutinized, there are few data summarizing the costs of both techniques. A systematic search was conducted in MED-LINE, Embase and Cochrane databases in August 2016 identifying articles comparing the costs or cost-effectiveness of CAS and CEA in patients with carotid artery stenosis. The primary endpoints were procedural costs, costs of hospital admission, and cumulative costs during follow-up. The secondary endpoint was health-related quality of life (utility) during follow-up. Combined overall effect sizes were calculated using random-effects models. The in-hospital costs were targeted to gain insight into the main reasons for expenditures associated with both procedures. The literature search identified 617 unique articles, of which five randomized controlled trials (RCTs) and 12 cohort studies were eligible for analysis. A total of 49,419 CAS and 361,699 CEA procedures were identified with a mean patient age 70 years. Sixty three percent were men and 52 % were symptomatic. Although the procedural costs were significantly higher by 51% for CAS (P ¼ .02) mainly driven by device and supplies cost (48% of total in-hospital costs), the length of stay favored CAS (P ¼ .006) resulting in the cost of the index hospital admission similar for CAS and CEA (0.25). The in-hospital stroke rate of patients in the included RCTs was twice as high after CAS than CEA (2.8% vs 1.4%), whereas the in-hospital myocardial rate was twice as high after CEA (3.2% vs 1.5%). Long-term cost analysis revealed no difference in costs or quality of life after one year of follow-up.
Comments: Cost is a component of the quality equation and will become an ever increasing determinate of physician and hospital reimbursement. It appears that CEA or CSA are equally cost competitive at the current time, CAS could realize a cost advantage but only if device and supply costs are decreased to realize that advantage. However, CAS is challenged by an increased risk of perioperative stroke, which is a critical patient quality outcome. Conclusions: The observed reduction of mortality risk from abdominal aortic aneurysm, peripheral arterial disease, and hypertension has never been seen before in the population screening literature and can be linked primarily to initiation of pharmacological therapy. Health policy makers should consider implementing combined screening whether no screening or isolated abdominal aortic aneurysm screening is currently offered.
Population Screening and Intervention for
Summary: Abdominal aortic aneurysm is the only cardiovascular disease targeted by population screening. In this study, the authors test the effect of screening and subsequent intervention for abdominal aortic aneurysm (AAA), peripheral arterial disease (PAD), and hypertension combined. It is a randomized controlled trial randomly allocating (1:1) all men aged 65 to 74 years living in the Central Denmark Region to screening for abdominal aortic aneurysm (> 3 cm), peripheral arterial disease (ankle/brachial index <0.9 or > 1.4), and hypertension (>160 mm Hg systolic or >100 mm Hg diastolic blood pressure), or to no screening. Allocation was by computergenerated random numbers from 1 to 100 in blocks of 1067 to 4392, stratified by 19 municipalities. Only the non-screening group and the investigator assessing outcomes were masked. Participants who were found to have abdominal aortic aneurysm or peripheral arterial disease were invited back for confirmation and eventual initiation of relevant pharmacological therapy. Participants with abdominal aortic aneurysm were offered annual imaging or surgical repair. Participants with suspected hypertension were referred to their general practitioner for treatment. Study patients had a total serum cholesterol concentration measured and if > 4.0 mmol/L were started on statin and aspirin therapy. The primary outcome was all-cause mortality assessed 5 years after randomization. Between October 8, 2008, and January 11, 2011, 50,156 participants were randomly allocated with 25,078 (50%) each in the screening and nonscreening groups. Four (<1%) participants in the screening group were lost to follow-up. There were no differences in baseline characteristics. Interesting, at retest, 11.1% of positive PAD diagnosis were false positives. Thirty-seven percent of patients were started on appropriate medical therapy, while 45.6% were already being treated. Only 32.8% of appropriate patients were motivated to engage in assisted smoking cessation. Of 619 men with AAA, 49.6% had repair within 5 years. After a median follow-up of 4.4 years (IQR, 3.9-4.8 years), 2566 (10.2%) of 25,074 participants in the screening group and 2715 (10.8%) of 25,078 in the non-screening group had died. This finding resulted in a significant hazard ratio of 0.93 (95% confidence interval [CI], 0.88-0.98; P ¼ .01), an absolute risk reduction of 0.006 (95% CI, 0.001-0.011), and a number needed to invite to screening to save one life was 169 (95% CI, 89-1811). Incidences of diabetes (3995 per 100 000 person-years in the screening group vs 4129 per 100,000 person-years in the nonscreening group), intracerebral hemorrhage (146 vs 140), renal failure (612 vs 649), cancer (3578 vs 3719), or 30 day mortality after cardiovascular surgery (44.57 vs 39.33) did not differ between groups.
Comments: A commentary to this article published in Lancet from Mayo is an excellent read and highlights my concerns with this article.
1 This article bundles two screening interventions known to be effective (abdominal aortic aneurysm and hypertension screening) with ankle/brachial index screening which currently has not be shown to be effective. Legitimizing ABI screening in this manner may place asymptomatic patients at risk if invasive intervention is the response. Furthermore, the cost of screening in the asymptomatic population where only w 10% of patients were found to have an abnormal ABI may not be cost ineffective. Remember, screening program should be accurate, not harmful (downstream testing, treatment, procedures, complications), and cost-effective among other requirements. Reference 1. Population-based screening for vascular disease. Ayoub C, Murad MH. Lancet 2017:1-2. https://doi.org/10.1016/S0140-6736(17)32250-X.
